From the National Clinical Research Center for Metabolic Diseases, Hunan Provincial Key Laboratory of Metabolic Bone Diseases, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Hunan, China.
the Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, National Commission of Health, Chinese Academy of Medical Science, Beijing, China.
Endocr Pract. 2020 Nov;26(11):1244-1254. doi: 10.4158/EP-2020-0124.
We sought to determine the long-term bioavailability of single doses of intramuscular (IM) vita-min D (D) in healthy adults.
Forty healthy volunteers with hypovitaminosis D received a single dose of 200,000, 400,000, or 600,000 IU intramuscular D or no treatment. Levels of 25-hydroxyvitamin D (25[OH]D) and 25-hydroxyvitamin D (25[OH]D) in serum were measured by liquid chromatography-tandem mass spectrometry. Vitamin D binding protein (DBP) and intact parathyroid hormone (iPTH), bone turnover markers (BTMs), and serum and urinary calcium were also measured.
After a single dose of D injection, the level of 25(OH)D increased slowly and reached a plateau at 8 weeks. The plateau remained stable for 12 weeks. The mean increase in 25(OH)D was 6.8, 9.6, or 15.6 ng/mL after injection of 200,000 IU, 400,000 IU, or 600,000 IU D. Although endogenous 25(OH)D levels were reduced by IM D, the total 25(OH)D levels increased by 5.0, 7.0, or 10.3 ng/mL in average after injection of 200,000 IU, 400,000 IU, or 600,000 IU D. The iPTH levels were also decreased by IM D. However, levels of serum calcium, BTMs, and DBP and urinary calcium were not altered by IM D.
A single dose of 200,000 IU, 400,000 IU, or 600,000 IU IM D raises total 25-hydroxyvitamin D levels by 5.0, 7.0, or 10.3 ng/mL on average for at least 12 weeks and reduces iPTH and endogenous 25(OH)D levels without affecting levels of serum calcium, BTMs, DBP, and urinary calcium.
我们旨在确定健康成年人单次肌内（IM）维生素 D（D）剂量的长期生物利用度。
40 名维生素 D 缺乏症患者接受了 20 万、40 万或 60 万 IU 肌内 D 或无治疗的单次剂量。通过液相色谱-串联质谱法测量血清 25-羟维生素 D（25（OH）D）和 25-羟维生素 D（25（OH）D）的水平。还测量了维生素 D 结合蛋白（DBP）和完整甲状旁腺激素（iPTH）、骨转换标志物（BTMs）以及血清和尿钙。
单次 D 注射后，25（OH）D 水平缓慢增加，并在 8 周时达到平台期。该平台在 12 周内保持稳定。注射 20 万、40 万或 60 万 IU D 后，25（OH）D 的平均增加量分别为 6.8、9.6 或 15.6ng/ml。尽管 IM D 降低了内源性 25（OH）D 水平，但注射 20 万、40 万或 60 万 IU D 后，总 25（OH）D 水平平均增加 5.0、7.0 或 10.3ng/ml。IM D 还降低了 iPTH 水平。然而，IM D 并未改变血清钙、BTMs、DBP 和尿钙水平。
单次注射 20 万、40 万或 60 万 IU IM D 可使总 25-羟维生素 D 水平平均升高 5.0、7.0 或 10.3ng/ml，至少持续 12 周，并降低 iPTH 和内源性 25（OH）D 水平，而不影响血清钙、BTMs、DBP 和尿钙水平。
